Palo Alto Networks' AI growth faces a higher valuation bar as analysts debate whether its 160% rally has priced in too much optimism.
AbbVie beats Pfizer as a dividend buy thanks to 53 years of payout growth, a solved patent cliff, and lower debt leverage. Here's the full breakdown.
As an Amazon Associate, Clay Tribune earns from qualifying purchases.
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
We carry advertising, and we like to know what gets read. Both use cookies. They are on unless you say otherwise, and you can opt out at any time from the link below.